CellCentric
Industry:
Oncology / Haematology
Website:
HBM contact:
Company status:
Private
Clinical-stage biotechnology company advancing inobrodib, a first-in-class, orally bioavailable p300/CBP inhibitor for the treatment of relapsed/refractory multiple myeloma and other cancers.
